The drug was previously available through the Cancer Drugs Fund, but with more data, NICE is backing routine access through the NHS.
The Swedish firm has treated the first two patients in a Phase I/II trial of the autologous neoantigen-directed lymphocyte therapy.
The company also continues to study Descartes-08 in other autoimmune diseases and has plans for a basket trial in pediatric patients.
The FDA didn't approve the therapy in EBV-positive post-transplant lymphoproliferative disease due to findings at a third-party manufacturing facility.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback